FZFan Zhang

Fan Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fan Zhang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Qiwen Deng

    Department of Infectious Diseases and Shenzhen Key Lab of Endogenous Infection, Shenzhen Nanshan People’s Hospital and the 6th affiliated Hospital of Guangdong Medical University, Shenzhen, China

    3 shared publications
  • Zhijian Yu

    School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University

    3 shared publications
  • Huang Zhen

    Department of Infectious Diseases, the Affiliated Shenzhen Nanshan Hospital of Guangdong Medical College, No 89, Taoyuan Road, Nanshan district, 518052 Shenzhen, China

    2 shared publications
  • Jin Yang

    Department of Infectious Diseases, the Affiliated Shenzhen Nanshan Hospital of Guangdong Medical College, No 89, Taoyuan Road, Nanshan district, 518052 Shenzhen, China

    2 shared publications
  • Zhong-Ming Zeng

    Department of Infectious Diseases and Shenzhen key lab for endogenous infection, Shenzhen Nanshan Hospital, Guangdong Medical College. No 89, Taoyuan Road, Nanshan district, Shenzhen 518052, China

    2 shared publications
  • Bing Bai

    Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, 518052, China.

    1 shared publication

Latest Publications

  • Open Access

    Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance

    by Fan Zhang, Bing Bai, Guang-Jian Xu, Zhi-Wei Lin, Gui-Qiu Li, Zhong Chen, Hang Cheng, Xiang Sun, Hong-Yan Wang, Yan-Wei Chen, et al.

    Mortality rates for patients with Staphylococcus aureus (S. aureus) infections have improved only modestly in recent decades and S. aureus infections remain a major clinical challenge This study investigated the in vitro antimicrobial activity of erevacycline (erava) against clinical S. aureus isolates from China, as well as the heteroresistance frequency of erava and sequence types (STs) represented in the sample. A sample of 328 non-duplicate clinical S. aureus isolates, including 138 methecillin-resistant (MRSA) and 190 methecillin-sensitive (MSSA) isolates, were collected retrospectively in China. Erava exhibited excellent in vitro activity (MIC50 ≤ 0.25 mg/L) against MRSA and MSSA, including isolates harboring Tet specific resistance genes. The frequency of erava heteroresistance in MSSA with erava MICs = 0.5 mg/L was 13.79% (4/29); no MRSA with erava MICs ≤0.5 mg/L exhibited heteroresistance. Heteroresistance- derived clones had no 30S ribosome subunit mutations, but their erava MICs (range, 1–4 mg/L) were suppressed dramatically in the presence of efflux protein inhibitors. Conclusively, erava exhibited excellent in vitro activity against S. aureus, however hints of erava heteroresistance risk and MIC creep were detected, particularly among MSSA with MICs of 0.5 mg/L.


  • Open Access

    Oral administration of interferon-α2b-transformed Bifidobacterium longum protects BALB/c mice against coxsackievirus B3-induced myocarditis

    by Zhijian Yu, Zhen Huang, Chongwen Shao, Yuanjian Huang, Fan Zhang, Jin Yang, Lili Deng, Zhongming Zeng, Qiwen Deng, Weiseng Zeng

    Multiple reports have claimed that low-dose orally administered interferon (IFN)-α is beneficial in the treatment of many infectious diseases and provides a viable alternative to high-dose intramuscular treatment. However, research is needed on how to express IFN stably in the gut. Bifidobacterium may be a suitable carrier for human gene expression and secretion in the intestinal tract for the treatment of gastrointestinal diseases. We reported previously that Bifidobacterium longum can be used as a novel oral delivery of IFN-α. IFN-transformed B. longum can exert an immunostimulatory role in mice; however the answer to whether this recombinant B. longum can be used to treat virus infection still remains elusive. Here, we investigated the efficacy of IFN-transformed B. longum administered orally on coxsackie virus B3 (CVB3)-induced myocarditis in BALB/c mice. Our data indicated that oral administration of IFN-transformed B. longum for 2 weeks after virus infection reduced significantly the severity of virus-induced myocarditis, markedly down regulated virus titers in the heart, and induced a T helper 1 cell pattern in the spleen and heart compared with controls. Oral administration of the IFN-transformed B. longum, therefore, may play a potential role in the treatment of CVB3-induced myocarditis.


  • Open Access

    Elevated IL-6 Receptor Expression on CD4+ T Cells contributes to the increased Th17 Responses in patients with Chronic Hepatitis B

    by Fan Zhang, Simin Yao, Jing Yuan, Mingxia Zhang, Qing He, Guilin Yang, Zhiliang Gao, Hong Liu, Xinchun Chen, Boping Zhou

    Increased numbers of Interleukin-17-producing CD4+ T cells (Th17) have been found in association with hepatitis B virus (HBV)-induced liver injury. However, the mechanism underlying the increase of Th17 responses in patients with HBV infection remains unclear. In this study, we investigate the possible regulatory mechanisms of increased Th17 responses in patients with chronic hepatitis B(CHB).


  • Open Access

    Hepatitis B virus core protein with hot-spot mutations inhibit MxA gene transcription but has no effect on inhibition of virus replication by interferon α

    by Yu Zhijian, Huang Zhen, Zhang Fan, Yang Jin, Deng Qiwen, Zeng Zhongming

    It has been reported that hepatitis B virus (HBV) core protein (HBc) can inhibit the transcription of human interferon-induced MxA gene. In this study, we investigated whether HBc protein mutations at hot spots (L60V, S87G and I97L) could still inhibit MxA transcription and the potential significance of this inhibition in virus replication in vitro. Our data indicated that the IFN-induced MxA mRNA expression level and MxA promoter activity was significantly down-regulated by mutant protein of HBc(I97L), compared to WT and the other two mutated HBc proteins(L60V or S87G). However, in Huh7 cells stably expressing WT or the mutated HBc proteins (L60V, S87G or I97L), IFN-α could inhibit the extra- and intracellular HBV DNA level and HBsAg secretion to a similar level compared to that in cells transfected with control plasmids. In conclusion, HBc protein with I97L mutation may play an especial role in suppressing the transcription of MxA gene. Moreover, the inhibitory effect on MxA gene transcription by the WT or mutated HBc proteins (L60V, S87G and I97L) has no impact on inhibition of HBV replication by IFN-α in Huh7 cells. The clinical significance of the inhibitory effect of MxA gene transcription by HBc protein requires further study.